Overview
- Editors:
-
-
Joseph Ragaz
-
Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
-
Irving M. Ariel
-
Foundation for Clinical Research Inc., New York, USA
Access this book
Other ways to access
Table of contents (27 chapters)
-
Therapy — Adjuvant
-
- A. Goldhirsch, R. D. Gelber
Pages 237-249
-
- P. Valagussa, R. Silvestrini, G. Bonadonna
Pages 250-259
-
-
Chemotherapy — Metastatic
-
Front Matter
Pages 283-283
-
-
-
Inflammatory Breast Cancer
-
Front Matter
Pages 317-317
-
- S. Waldman, L. M. Toonkel, E. Davila
Pages 319-333
-
- J. P. Ferriere, A. Janin, F. Kwiatkowski, M. Legros, Y. J. Bignon, P. Chollet et al.
Pages 334-344
-
- A. Janin, R. Plagne, J. P. Ferriere, Y. Fonck, M. De Latour, M. Bourges
Pages 345-353
-
Stage III Breast Cancer
-
Front Matter
Pages 355-355
-
-
- G. N. Hortobagyi, A. U. Buzdar
Pages 382-415
-
- S. M. Swain, M. E. Lippman
Pages 416-434
-
Autologous Bone Marrow Transplantation
-
Front Matter
Pages 435-435
-
-
- K. H. Antman, J. P. Eder, A. Elias, T. C. Shea, B. Teicher, W. D. Henner et al.
Pages 447-470
-
Therapeutic Aspects of Tumor Biology Research
-
Front Matter
Pages 471-471
-
-
Summary
-
Front Matter
Pages 491-491
About this book
The many advances in breast cancer research, as well as the large quantity of published material, make it very difficult to gain insight into the global aspects of cancer management. To follow and understand all the new developments is becoming a major challenge. For this reason, the editors decided to bring together a group of top researchers in breast cancer to provide a comprehensive, yet readable conceptual review of the state of the art of breast cancer diagnosis and therapy. The proposal to focus the review on the quantitative assessment of the risk at diagnosis, the determination of which may permit selective therapies for individual patients, was met with enthusiastic approval, resulting in the present volume with contributions by the leading investigators in the field. While the volume relating to diagnosis, published re cently, focused on efforts leading to refinement at diagnosis of risk criteria sensitive enough to reliably distinguish the low- and high-risk categories, the second volume, by provid ing a review of the main problems and results of therapy given to high-risk patients, can be considered as a continua tion of the first book. A refined risk assessment at diagnosis and the application of the most suitable treatments to well selected individuals are the most important steps towards avoiding the present worrisome reality of overtreating the low risk and undertreating the high-risk patients. The first few chapters of the present volume offer an insight into the general management of early breast cancer.
Editors and Affiliations
-
Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
Joseph Ragaz
-
Foundation for Clinical Research Inc., New York, USA
Irving M. Ariel